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ABSTRACT
PIN1 is a peptidyl-prolyl cis/trans isomerase (PPIase) that regulates multiple 
signaling pathways to control cell fate and is found to be over-expressed in cancers, 
including hepatocellular carcinoma (HCC). However, the regulation of PIN1 in HCC 
remains poorly defined. Micro-RNAs (miRNAs) have been reported to play a pivotal 
role in oncogenesis by targeting the 3′-untranslated region (UTR) of mRNAs encoded 
by oncogenes and tumour suppressor genes, thereby suppressing the levels of both 
oncoproteins and tumour suppressors. In this report, we aimed to identify miRNAs 
that suppress PIN1 expression and to determine their role in HCC. By searching the 
TargetScan database, miR-874-3p was identified as a potential negative regulator 
of PIN1. miR-874-3p was demonstrated to bind the 3′UTR of PIN1 mRNA directly to 
suppress expression of PIN1. Functionally, over-expression of miR-874-3p in HCC cell 
line PLC/PRF/5 inhibited cell growth and colony formation in-vitro, and promoted 
cellular apoptosis. Furthermore, these tumour suppressive functions conferred 
by miR-874-3p were abrogated by over-expression of PIN1. Similarly, expression 
of miR-874-3p in PLC/PRF/5 with PIN1 knocked-down did not further suppress 
cellular proliferation, suggesting that PIN1 was a major target of miR-874-3p. More 
importantly, miR-874-3p was found to be down-regulated in HCC tissues and its 
expression was negatively correlated with that of PIN1. Down-regulation of miR-874-3p  
was also associated with poorly differentiated tumour cells, more advanced staging, 
and inferior patient outcomes. In addition, over-expression of miR-874-3p suppressed 
tumour growth in vivo. Taken together, our data suggested that miR-874-3p plays a 
tumour suppressive role in HCC through down-regulation of PIN1.
INTRODUCTION
Peptidyl-prolyl cis-trans isomerase NIMA-interacting 
1 (PIN1) is an enzyme that, through its WW domain, binds 
to proteins with specific phosphorylated serine or threonine 
residues preceding proline (pSer/Thr-Pro), leading to their 
conformational and functional changes [1]. This is mediated 
by isomerization of the pSer/Thr-Pro peptide bonds with 
its prolyl isomerase (PPIase) domain, resulting in alteration 
of the activity, stability, protein-protein interaction and 
sub-cellular localization of these proteins [2, 3]. Because 
of these functions, PIN1 modulates many key cellular 
processes, such as cell cycle progression, cell proliferation 
and apoptosis. Consequently, dysregulation of PIN1 may 
result in tumour development [4–6]. Over-expression of 
PIN1 is found in many cancers, including hepatocellular 
carcinoma (HCC) [7]. We have demonstrated that PIN1 
is over-expressed in over 50% of HCC and its over-
expression leads to β-catenin and cyclin D1 accumulation 
in tumour cells [8]. Moreover, mouse xenograft experiments 
confirmed that PIN1 over-expression contributes to 
hepatocarcinogenesis and enhances the oncogenic function 
of the hepatitis B virus x-protein (HBx) in HCC [9, 10]. In 
addition, PIN1 also inhibits apoptosis in HCC by enhancing 
the anti-apoptotic function of survivin [11]. These 
important and diverse functions of PIN1 in promoting the 
malignant properties of HCC cells suggest that therapeutic 
intervention targeting PIN1 may be efficacious in HCC. 
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Despite the biologic and potential therapeutic importance 
of PIN1 in HCC, the regulation of its expression remains 
poorly understood. The human PIN1 gene is located in 
chromosome 19, and there is no evidence yet to suggest 
that the PIN1 gene is amplified in cancers [12]. One of the 
early studies has shown that PIN1 level is promoted by the 
retinoblastoma/E2F pathway [13]. E2F proteins bind to the 
PIN1 promoter and activate gene transcription. It has been 
postulated that the frequently dysregulated retinoblastoma 
pathway is the cause of PIN1 over-expression in breast 
cancer [13]. However, whether this proposition is valid in 
other cancer types remains to be defined.
MiRNAs are small non-coding RNAs that 
regulate gene expression at both transcriptional and 
post-transcriptional levels [14]. Aberrant expression 
of miRNAs has been shown to be associated with 
pathogenesis of cancers [14]. While some miRNAs are 
oncogenic in nature (oncomir), there are miRNAs that 
possess tumour suppressive action, and their levels are 
decreased in cancer cells. In HCC, a global reduction 
of miRNAs expression is tightly associated with tumour 
progression [15]. Many of these “tumour-suppressive” 
miRNAs suppress the expression of genes that positively 
promote tumour development and progression. More 
recently, miRNAs-miR-200c and miR-296-5p have been 
shown to inhibit PIN1 expression in breast and prostate 
cancer, respectively [6, 16]. However, no miRNA has been 
reported to reduce PIN1 expression in HCC. 
To identify miRNAs that may regulate PIN1 expression 
in HCC, we performed an initial search (TargetScan 6.2) and 
identified 102 miRNAs targeting the 3′-untranslated region 
(UTR) of PIN1 mRNA. Six potential miRNAs (miR-296-5p, 
miR-874-3p, miR-4665-3p, miR-3173-5p, miR-1587-5p 
and miR-1207-5p) with the highest total context score were 
selected for further testing in this study.
RESULTS
Down-regulation of PIN1 suppressed cell 
proliferation and colony formation, and induced 
apoptosis in HCC cell lines
Specific small interfering RNA (siRNA) was used to 
suppress PIN1 expression (Figure 1A). Down-regulation 
of PIN1 expression resulted in decreased proliferation 
and in-vitro colony formation of PLC/PRF/5 and HepG2 
cells (Figure 1B and 1C). Moreover, PIN1 depletion also 
enhanced staurosporine(STS)-induced cellular  apoptosis 
(Figure 1D and 1E). These results confirmed and validated 
that growth and survival of HCC cells were positively 
modulated by PIN1 expression.
miR-296-5p and miR-874-3p decreased PIN1 
expression
Initial search revealed that 102 miRNAs may 
target PIN1 mRNA 3′UTR to regulate PIN1 expression 
(TargetScan 6.2). Six potential miRNAs (miR-296-5p, 
miR-874-3p, miR-4665-3p, miR-3173-5p, miR-1587-5p 
and miR-1207-5p) were selected for further experiments 
based on their high total context scores. Among them, only 
miR-296-5p and miR-874-3p were found to significantly 
down-regulate PIN1 protein in HCC cell lines HepG2 
and PLC/PRF/5 (Figure 2A and Supplementary Figure 1). 
To further validate the effect of these miRNAs in PIN1 
down-regulation, miR-296-5p and miR-874-3p were 
transiently transfected into HepG2, PLC/PRF/5, and human 
embryonic kidney 293T cells. Consistently, miR-296-5p and 
miR-874-3p were demonstrated to decrease mRNA and 
protein levels of PIN1 in all 3 different cell lines (Figure 2B 
and 2C). To determine the function and specificity of 
miRNAs, specific miRNA inhibitors were co-transfected 
with their corresponding miRNAs in 293T cells. Expectedly, 
miR-296-5p and miR-874-3p inhibitors abolished the PIN1 
down-regulation induced by their corresponding miRNAs 
(Figure 2D). These results showed that miR-296-5p and 
miR-874-3p specifically decreased PIN1 expression.
The expression of miR-874-3p was significantly 
down-regulated in HCC and negatively 
correlated with PIN1 
To evaluate the clinical relevance and significance 
of these regulatory miRNAs of PIN1, we analysed the 
expression levels of the 6 identified-miRNAs using the 
online HCC miR-Seq dataset of The Cancer Genome Atlas 
(TCGA) (http://cancergenome.nih.gov/). Only miR-296-5p 
and miR-874-3p were found to be detectable in HCC 
tissues and non-tumourous liver tissue (NT), whereas the 
other four miRNAs were not. Moreover, miR-874-3p, but 
not miR-296-5p, was significantly down-regulated in HCC 
while compared with NT (Supplementary Figure 2). We 
further examined the expression levels of miR-296-5p 
and miR-874-3p, and their correlation with that of PIN1 in 
48 primary HCC samples and their paired NT. As shown 
in Figure 3A, miR-296-5p and miR-874-3p expression 
was negatively correlated with that of PIN1 (p = 0.0004 
and p < 0.0001, respectively, Pearson analysis). The 
expressions of PIN1, miR-296-5p and miR-874-3p in 
HCC were further quantified in tumour samples and 
compared with their paired NT. PIN1 was found to be 
over-expressed in 85.4% of cases, whereas miR-296-5p 
and miR-874-3p were down-regulated in 58.3% and 
70.8% of cases (Figure 3B). However, only miR-874-3p 
was demonstrated to be significantly lower in tumour, 
as compared with NT, consistent with the data obtained 
from TCGA database (Figure 3C). Correlation with 
clinicopathologic parameters showed that down-regulation 
of miR-874-3p was associated with poorly differentiated 
tumour cells and more advanced tumour staging (Table 1). 
More importantly, down-regulation of miR-874-3p, 
but not miR-296-5p, was also associated with inferior 
overall survival and disease free survival of HCC patients 
(Figure 4). Our results, therefore, suggested miR-874-3p 
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to be a clinically and pathologically relevant negative 
regulator of PIN1, and might potentially play a tumour 
suppressive role in HCC.  
Direct binding of miR-874-3p to 3′UTR of PIN1 
mRNA
To determine if miR-874-3p specifically bound 
to 3′UTR of PIN1 mRNA, we examined the interaction 
between PIN1 mRNA 3′UTR and miR-874-3p. There 
are two potential miR-874-3p binding sites in the PIN1 
mRNA 3′UTR (Figure 5A). Luciferase assays with 
plasmids containing PIN1 mRNA 3′UTR that was wild-
type (pPIN1-3′UTR-WT) and mutated at the miR-874-3p-
binding-sites (pPIN1-3′UTR-874mutant) were performed 
(Figure 5B). As shown in Figure 5C, over-expression 
of miR-874-3p significantly reduced the luciferase 
reporter activity of pPIN1-3′UTR-WT but not pPIN1-
3′UTR-874mutant. Moreover, concomitant expression of 
miR-874-3p specific inhibitor restored the inhibition of 
Figure 1: Down-regulation of PIN1 suppressed cell proliferation and colony formation, and enhanced apoptosis of HCC 
cell lines. (A) Western immunoblots showing down-regulation of PIN1 by siRNA in HepG2 and PLC/PRF/5. β-actin was used as an internal 
control. (B) PIN1 knock-down by siRNA suppressed proliferation of HepG2 and PLC/PRF/5 cells as shown by MTT assay. (**P ≤ 0.01, and 
***P ≤ 0.001, paired t-test) (C) In-vitro assay showing significant suppression of colony formation by HepG2 and PLC/PRF/5 cells after 
PIN1 knocked-down. (D) FACS analysis scatter plots showing the increase in apoptosis of PLC/PRF/5 cells (positive staining for annexin-V) 
after PIN1 knocked-down. (E) Diagram illustrating the significant increase in apoptotic cells after PIN1 knocked-down in PLC/PRF/5. Three 
independent sets of experiments were performed. (*P ≤ 0.05, paired t-test).
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luciferase reporter activity of pPIN1-3′UTR-WT, showing 
that miR-874-3p bound to PIN1 mRNA 3′UTR specifically 
to suppress PIN1 expression.
Decrease in cell proliferation and in-vitro colony 
formation, and increase in apoptosis mediated by 
miR-874-3p in HCC 
To examine the functional significance of miR-
874-3p in HCC cells, we performed MTT, in-vitro colony 
formation, and apoptosis assays in PLC/PRF/5 cells 
with or without miR-874-3p over-expression. Results 
from MTT and in-vitro colony formation assays showed 
that expression of miR-874-3p significantly inhibited 
proliferation and impaired colony formation of PLC/
PRF/5 cells (Figure 6A–6C). Furthermore, miR-874-3p 
expression enhanced STS-induced apoptosis (Figure 6D 
and 6E). These results suggested that miR-874-3p assumed 
a tumour suppressive role in HCC cells. 
The tumour suppressive role of miR-874-3p was 
mediated by PIN1 down-regulation in HCC
To demonstrate that the tumour suppressive function 
of miR-874-3p was mediated through PIN1 down-
regulation, PIN1 was over-expressed by PIN1 cDNA 
Figure 2: Over-expression of miR-296-5p and miR-874-3p decreased PIN1 mRNA and protein expression levels. 
(A) Of the 6 miRNAs tested, only miR-296-5p and miR-874-3p suppressed PIN1 expression in HepG2 cells as examined with western 
immunoblot. (B) Western blot showing PIN1 down-regulation in all 3 cell lines transfected with miR-296-5p and miR-874-3p (C) PIN1 
mRNA was suppressed by miR-296-5p (left panel) and miR-874-3p (right panel) as determined by RT-qPCR. (*P ≤ 0.05, **P ≤ 0.01, and 
***P ≤ 0.001, paired t-test) (D) Western blots showing that miR-296-5p and miR-874-3p inhibitors abolished the PIN1 regulation induced 
by their corresponding miRNAs. 
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transfection in PLC/PRF/5 cells with or without miR-
874-3p expression. The level of over-expressed PIN1 
protein in PLC/PRF/5 with PIN1 cDNA transfection 
was not affected by miR-874-3p because the PIN1 
cDNA construct did not contain a 3′UTR, hence the 
transcribed PIN1 mRNAs was not targeted by miR-874-3p 
(Figure 7A). In PLC/PRF/5 cells, PIN1 over-expression 
successfully abrogated miR-874-3p-mediated suppression 
of cell proliferation (Figure 7B). Similarly, the reduced 
in-vitro colony formation capability of PLC/PRF/5 with 
miR-874-3p expression was also reverted by PIN1 over-
expression (Figure 7C and 7D). Furthermore, PIN1 over-
expression also decreased cellular apoptosis that was 
enhanced by miR-874-3p expression (Figure 7E). These 
results showed that the tumour suppressive function of 
miR-874-3p was mediated through its down-regulation of 
PIN1. In addition, to further validate the role of PIN1 in 
miR-874-3p mediated tumour suppressive function, miR-
874-3p was over-expressed in PIN1-silenced cells (PLC/
PRF/5 with PIN1 knocked-down by siRNA). MTT assay 
showed that miR-874-3p over-expression did not suppress 
cell proliferation in PIN1-silenced cells, suggesting that 
PIN1 is an important downstream target of miR-874-3p 
(Supplementary Figure 3). 
miR-874-3p suppressed HCC cell growth in vivo
We established a stable clone of PLC/PRF/5 cells 
expressing miR-874-3p to further examine the tumour 
suppressive function of miR-874-3p in vivo. Control 
sequence (pcDNA6.2-Ctl) or miR-874-3p (pcDNA 
6.2-874) was cloned into pcDNA6.2 plasmid and 
stably expressed in PLC/PRF/5 cells. Cells were then 
subcutaneously injected in nude mice and the tumour 
growth was monitored. Consistent with the results of the 
in vitro experiments, PLC/PRF/5 cells with miR-874-3p 
expression formed significantly smaller tumours in vivo, 
as compared to the control (Figure 8).
DISCUSSION
Despite the importance of miRNAs and PIN1 in the 
pathogenesis of HCC, the relationship between miRNAs 
and PIN1 in HCC has not been examined. In this study, 
Figure 3: The expression of miR-874-3p was down-regulated in primary HCC tissues and correlated negatively with 
PIN1. (A) The expression of PIN1 was negatively correlated with miR-296-5p (left) and miR-874-3p (right) (B) The expression of PIN1 
(left panel), miR-296-5p (middle panel) and miR-874-3p (right panel) for each paired sample was represented as log2 fold change of the 
tumour relative to the non-tumourous tissue (T/NT). (C) The relative expression of miR-296-5p, miR874-3p and PIN1 in tumour (T) and 
non-tumourous tissue (NT) were shown by scatter plot. (*P ≤ 0.05, and ***P ≤ 0.001; ns = no significance, Mann Whitney test). 
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we identified miR-874-3p as a tumour suppressive miRNA 
that down-regulated PIN1 expression in HCC. Although 
we found that miR-296-5p also decreased PIN1 expression, 
as was previously reported in prostate cancer, there was no 
differential expression of miR-296-5p between HCC and 
the corresponding non-tumourous liver tissues. Therefore, 
miR-296-5p might not directly contribute to the neoplastic 
phenotype. However, HCC typically evolves through a 
cirrhotic stage, meaning that the surrounding non-tumour 
tissues are also in fact abnormal. Hence, a role of miR-
296-5p in the multistep process of hepatocarcinogenesis 
cannot be totally excluded.
In contrast, miR-874-3p was significantly down-
regulated in HCC as compared with non-tumourous tissue. 
More importantly, down-regulation of miR-874-3p in HCC 
was associated with poorly differentiated tumour, higher 
tumour staging and inferior survivals, underscoring the 
tumour suppressive function of miR-874-3p. miR-874-3p 
has been consistently shown in various tumour types to be a 
tumour suppressive miRNA through regulation of STAT3, 
CDK9 and E2F3 expression [17–19]. On the other hand, 
miR-296-5p has been reported to function as both tumour 
suppressive and oncogenic miRNA through controlling the 
expression of p21 and PLK1 respectively [20, 21]. In HCC, 
our data suggested that miR-874-3p played a more critical 
role than miR-296-5p in carcinogenesis.  
PIN1 is over-expressed in cancers of many organs, 
including breast, lung, and prostate, and is involved 
in carcinogenesis [22–24]. Our group has also shown 
that PIN1 is up-regulated in 50–70% of HCC [8, 10]. 
However, the control of PIN1 expression in HCC has not 
been previously investigated. Data in this report showed 
that miR-874-3p controlled PIN1 mRNA and protein 
expression through targeting of PIN1 mRNA 3′UTR. 
Moreover, there was a significant negative correlation 
between PIN1 and miR-874-3p expression. Based on these 
observations, we propose that the high expression of PIN1 
is partly contributed by the down-regulation of miR-874-3p 
during hepatocarcinogenesis. The mechanisms underlying 
the down-regulation of miR-874-3p remain to be defined.
Given the pathogenic role of PIN1 in HCC, PIN1 
inhibition represents a novel approach for the treatment of 
HCC. PIN1 inhibitors such as juglone, PiB, and all-trans 
retinoic acid have been used successfully in in-vitro studies 
to inhibit tumour growth, supporting the role of PIN1 as 
a potential therapeutic target [25, 26]. In addition to small 
molecule inhibitors, tumour suppressive miRNAs are also 
potential anti-cancer agents [27]. The first miRNA mimic-
MRX34 has already reached to the stage of phase 1 clinical 
study in patients with primary or metastatic HCC [28]. 
Observations in this study suggest that miR-874-3p may also 
be a potential therapeutic agent for HCC.  This proposition 
warrants further laboratory and clinical evaluation. 
MATERIALS AND METHODS
Cell culture and transfection
Human HCC cell lines, HepG2 and PLC/PRF/5, 
and human embryonic kidney 293T cells were cultured 
Table 1: Clinicopathological correlation of down-regulation of miR-296-5p and miR-874-3p in 
HCC patients
   miR-296-5p downregulation miR-874-3p downregulation
 no. of patients No Yes ^p No Yes ^p
Sex
 
Male 38 18 20  27 11
0.4859
Female 12 9 3 0.1119 7 5
Liver cirrhosis
 
Present 28 11 17  22 6  
Absent 22 16 6 0.0244 12 10 0.1256
Tumour nodule
 
≥ 2 10 6 4  7 3  
1 40 21 19 0.7356 27 13 1
Cell differentiation*  I–II 19 5 14  17 2  
III–IV 31 22 9 0.0033 17 14 0.0134
Tumour size
 
> 5 cm 37 21 16  23 14  
≤ 5 cm 13 6 7 0.5369 11 2 0.1792
pTNM stage# I/II 13 5 8  12 1  
III/IV 34 20 14 0.3279 19 15 0.0359
*Edmondson grading.
#Pathological Tumor-Node-Metastasis stage.
^p-value calculated by Fisher’s exact test.  
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in Dulbecco’s modified Eagle’s medium (DMEM) (Life 
TechnologiesTM, MA, USA) with 10% fetal bovine serum 
(Life TechnologiesTM, MA, USA) and antibiotics (Life 
TechnologiesTM, MA, USA). All cell lines were grown in 
a humidified incubator at 37°C and supplemented with 5% 
CO2–enriched atmosphere. HepG2, PLC/PRF/5 and HEK 
293T cells were seeded in antibiotic free culture medium 
for 24 hours, followed by transfection with 60 nM of siRNA 
(siNeg and siPIN1) (Qiagen, Germany), mimic microRNAs 
(miR-Neg, miR-296-5p and miR-874-3p) (Applied 
BiosystemsTM, MA, USA) or microRNA inhibitors (miR-
Neg, miR-296-5p and miR-874-3p) (Applied BiosystemsTM, 
MA, USA) using Lipofectamine RNAiMAX (Life 
TechnologiesTM, MA, USA). 
HCC patient samples
Primary HCC tumour samples, each paired with 
its non-tumourous adjacent tissue, were obtained from 
surgical resection at Queen Mary Hospital, Hong Kong. 
Fresh tissues were immediately frozen in liquid nitrogen 
and stored at −80°C. The use of the clinical specimens for 
this study was approved by Institutional Review Board of 
the University of Hong Kong and the Hospital Authority 
of Hong Kong. 
Plasmids and site-directed mutagenesis
The construction of pEGFP-PIN1 and pCDNA-
PIN1 has been described previously[10, 11]. Wild-type 
PIN1 3′UTR was cloned into the pmiR-reporter vector to 
generate pPIN1-3′UTR-WT. Primer sequences used for 





Two sites on the PIN1 3′UTR were mutated in the 
Figure 4: HCC patients with miR-874-3p down-regulation showed inferior overall and disease-free survivals. Kaplan-
Meier survival curves showing that HCC patients with down-regulation of miR-874-3p (right panels), but not miR-296-5p (left panels), 
exhibited lower overall (upper panels) and disease-free (lower panels) survival rates. P values were shown in the figure. 
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pPIN1-3′UTR-WT to generate pPIN1-3′UTR-874mutant 
by site-directed mutagenesis (QuikChange II, Agilent 
Technologies, CA, US). Specific primers were designed 
(QuikChange Primer Design, Agilent Technologies, CA, 
US), and DNA sequences of all constructs were verified 
by direct sequencing.
Control oligo and miR-874-3p were cloned into 
pcDNA6.2 plasmid by BLOCK-iT Pol II RNAi Expression 
Vector Kits (Life TechnologiesTM, MA, USA). The sequences 









Establishment of PIN1 and miR-874-3p over-
expressing PLC/PRF/5 stable clones
PLC/PRF/5 cells were transfected with 
pCDNA3.1(-) and pCDNA-PIN1 for 48 hours. Stable 
clones over-expressing PIN1 were selected after 2 week 
with 5 mg/ml G418 (Sigma-Aldrich, MO, USA) in DMEM 
medium and 10% fetal bovine serum (Life TechnologiesTM, 
MA, USA). Selected clones were expanded in 24-well 
plate and the protein expression of PIN1 was examined 
by western blot. For miR-874-3p, pcDNA6.2-874 plasmid 
was transfected into PLC/PRF/5 cells for 48 hours. The 
transfected cells were then selected by 20 ug/ml Blasticidin 
Figure 5: Direct binding of miR-874-3p to PIN1 3′UTR. (A) Diagram showing the two predicted miR-874-3p binding sites on 
3′UTR of PIN1 mRNA. (B) Sequences showing the putative miR-874-3p binding sites on PIN1 3′UTR and the mutated miR-874-3p binding 
sites generated by site-directed mutagenesis (C) Dual luciferase reporter assay showing significant suppression of luciferase activity only 
when miR-874-3p was partnered with wild-type PIN1 3′UTR, and miR-874-3p inhibitor restoring the decreased luciferase activity. The 
relative luciferase activities were normalized with Renilla activity and the miR-Neg control. Experiments were repeated in triplicates. 
(*P ≤ 0.05; ns = no significance, unpaired t-test).
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(Life TechnologiesTM, MA, USA) in DMEM medium and 
10% fetal bovine serum (Life TechnologiesTM, MA, USA) 
for 2 weeks. Selected clones were then expanded and the 
expressions of miR-874-3p and PIN1 were examined by 
qRT-qPCR and western blot respectively. 
Reverse transcription and quantitative polymerase 
chain reaction (qRT-qPCR)
Total RNA was extracted by Trizol reagent (Life 
TechnologiesTM, MA, USA). For PIN1 and 18S rRNA, 
0.5 µg RNA was reverse transcribed to cDNA by 
SuperScript® III Reverse Transcriptase (Life TechnologiesTM, 
MA, USA). The resulting cDNAs were quantified by 
quantitative PCR with Sybr Green master mix (Applied 
BiosystemsTM, MA, USA) and specific primers for PIN1 
and 18S rRNA detection. The specific primers used for PCR 
were:
PIN1 forward: 5′-TCGCACCTGCTGGTGAA-3′.
PIN1 reverse: 5′- ACTGTGAGGCCAGAGAC-3′.
18S rRNA forward: 5′-AAACGGCTACCACATC
CAAG-3′.
18S rRNA reverse: 5′-CGCTCCCAAGATCCAA
CTAC-3′.
For miRNAs, 10 ng RNA was used for target-
specific reverse transcription (TaqMan MicroNRA Reverse 
Transcription Kit, Applied BiosystemsTM, MA, USA). 
Levels of miR-296-5p, miR-874-3p and U6 snRNA 
Figure 6: miR-874-3p suppressed cell proliferation and in-vitro colony formation, and enhanced apoptosis of HCC 
cells. (A) Increased expression of miR-874-3p significantly suppressed cell proliferation of PLC/PRF/5 cells as determined by MTT assay. 
(*P ≤ 0.05, paired t-test) (B) miR-874-3p suppressed in-vitro colony formation of PLC/PRF/5 cells. (C) Diagram showing decreased in 
colonies formed by PLC/PRF/5 cells with miR-874-3p expression. (*P ≤ 0.05, unpaired t-test) (D) FACS analysis scatter plots showing 
increased apoptotic (annexin-V positive) cells with miR-874-3p expression. (E) Diagram showing increased numbers of apoptotic cells 
after STS treatment in PLC/PRF/5 cells with miR-874-3p expression. Experiments were repeated in triplicates. (**P ≤ 0.01, paired t-test).
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were examined by TaqMan® MicroRNA Assay (Applied 
BiosystemsTM, MA, USA).
Protein extraction and western blotting
Total protein was extracted with RAPI buffer 
(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% (v/v) 
NP-40, 1X protease inhibitor cocktail and 0.25% (w/v) 
sodium deoxycholate, pH 7.4). Protein was size-fractionated 
by SDS-PAGE and transferred to nitrocellulose membrane 
(Bio-Rad Laboratories, CA, USA). The membranes were 
blocked with 1× TBST buffer (20 mM Tris pH 7.5, 150 mM 
NaCl and 0.1% Tween 20) with 5% w/v non-fat dry milk, 
incubated with specific primary antibodies at 4°C overnight, 
washed with 1× TBST, and then incubated with HRP-
conjugated anti-mouse or anti-rabbit IgG antibodies for 
2 hours at room temperature. The expression level of various 
proteins was detected by enhanced chemiluminescence 
(EMD Millipore, MA, US) and ChemiDoc Imaging system 
(Bio-Rad Laboratories, CA, USA). Anti-PIN1 (Calbiochem, 
CA, USA) and anti-actin (Sigma-Aldrich. MO, US) 
antibodies were used for western blots.
Figure 7: miR-874-3p regulated cell proliferation, colony formation as well as cellular apoptosis via down-regulation 
of PIN1 expression. (A) Western blots showing the high level of PIN1 in PLC/PRF/5 cells stably transfected with PIN1 cDNA (PLC 
PIN1 OE) irrespective of miR-874-3p expression. (B) PIN1 over-expression abolished the suppressed cell proliferation mediated by 
miR-874-3p. (*P ≤ 0.05, **P ≤ 0.01, unpaired t-test) (C) PIN1 over-expression abrogated the suppressed colony formation mediated by 
miR-874-3p. (D) Diagram showing PIN1 over-expression ameliorated the inhibition of colony formation of PLC/PRF/5 cells by miR-874-3p. 
(**P ≤ 0.05, ***P ≤ 0.001 , ns = no significance, unpaired t-test) (E) Diagram showing PIN1 over-expression suppressed the enhancement 
of cellular apoptosis mediated by miR-874-3p. (*P ≤ 0.05, ***P ≤ 0.001, ns = no significance, unpaired t-test).
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MTT assay and in-vitro colony formation assay
Twenty hours after transfection, cells were seeded in 
96-well plate one day prior to MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. Cells 
were incubated at 37°C for 4 hours with 1 mg/ml MTT 
(Sigma-Aldrich, MO, USA) in DMEM medium with 10% 
FBS before measurement with CLARIOstar microplate 
reader at indicated days. For in-vitro colony formation 
assay, 0.5% crystal violet (Sigma-Aldrich, MO, USA) with 
20% methanol was used to fix and stain cells 15 days after 
transfection.
Luciferase reporter assay
HEK 293T cells were transfected with 60 nM 
microRNA mimics or inhibitors (Applied BiosystemsTM, 
MA, USA) for 24 hours (Lipofectamine RNAiMAX, Life 
TechnologiesTM, MA, USA), followed by transfection with 
10 ng of wild type or mutated PIN1 3′UTR reporter and 
1 ng of Renilla plasmid for 48 hours (ViaFect transfection 
reagent, Promega, WI, USA). The luciferase activities 
were detected by Dual-luciferase reporter assay (Promega, 
WI, USA). Briefly, cells were lysed with 100 µl of 1X 
Passive Lysis buffer at room temperature and 20 µl of cell 
lysate was used for the detection of luciferase activity. 
Apoptotic cell analysis
PLC/PRF/5 cells were seeded a day before 
staurosporine (STS; 0.5 mM) treatment. Cells were stained 
with annexin and 7AAD by Annexin V-Phycoerythrin 
(Annexin V-PE) and 7-AAD Apoptosis Detection Kit 
(BD Biosciences, NJ, USA). The apoptotic cells were 
then detected by FACS with Cytomics FC500 (Beckman 
Coulter, CA, USA). 
In vivo xenograft experiment
Animal study was approved by the Committee on 
the Use of Live Animals in Teaching and Research of 
the University of Hong Kong. Human tumour Xenograft 
model was established in BALB/cAnN-nu (nude) mice 
(Charles River Lab, USA). 2 × 106 PLC/PRF/5 cells with 
Figure 8: Expression of miR-874-3p suppressed HCC tumour growth in vivo. (A) 2 × 106 PLC/PRF/5 cells with control sequence 
(pCDNA6.2-Ctl) or miR-874-3p (pCDNA6.2-874) over-expression were subcutaneously injected in the left flank and right flank of nude mice 
respectively. Tumour development was monitored for 28 days after injection. The size of tumours developed from miR-874-3p expressing 
cells was smaller than those of the control cells. (B) The development of tumours from miR-874-3p expressing cells was significantly slower. 
(C) RT-qPCR showing the higher miR-874-3p expression in the tumours derived from miR-874-3p expressing cells. (D.) Western blot showing 
the lower expression of PIN1 in one of the representative tumours derived from miR-874-3p expressing cells. (*P ≤ 0.05, **P ≤ 0.01, paired 
t-test).
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pcDNA6.2-Ctl or pcDNA6.2-874 stable expression were 
subcutaneously injected in the left flank and right flank of 
nude mice respectively. Tumours volume were measured 
every 2–3 days and were calculated as (L × W2)/2. L 
represented the length while W represented the width of 
tumour. After 28 days, mice were sacrificed and tumours 
were excised. 
Statistical analyses
Statistical analyses were performed with PRISM 5 
software (GraphPad). Categorical data were analysed with 
χ2 test, and numerical data by t-tests. Survival analysis was 
performed with Kaplan-Meier method.
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